CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

Core Insights - CAMP4 Therapeutics is focused on developing regulatory RNA-targeting therapeutics aimed at upregulating gene expression to restore healthy protein levels for treating various genetic diseases [1][3] - The company will present three oral presentations at the 28th Annual Meeting of the American Society of Gene and Cell Therapy, highlighting their research and interim safety data from their Phase 1 clinical trial of CMP-CPS-001 [1][2] Group 1: Presentations Details - The first presentation will discuss targeting regulatory RNAs with antisense oligonucleotides for the potential treatment of urea cycle disorders, presented by Dan Tardiff, Ph.D. on May 16, 2025 [2] - The second presentation will also be by Dan Tardiff, Ph.D., focusing on the potential treatment of SYNGAP1-related disorders, scheduled for the same session [2] - The third presentation will provide interim safety readouts from a first-in-human double-blind, placebo-controlled study of CMP-CPS-001, presented by Yuri Maricich, M.D. on May 16, 2025 [2] Group 2: Company Overview - CAMP4 Therapeutics is developing disease-modifying treatments for over 1,200 genetic diseases where increasing healthy protein levels may provide therapeutic benefits [3] - The company's proprietary RAP Platform™ is designed to map regulatory RNAs and generate therapeutic candidates targeting regRNAs associated with haploinsufficient and recessive partial loss-of-function disorders [3]